Limited coverage criteria – linagliptin and linagliptin-metformin

Last updated on March 2, 2026

Coverage for this medication is under National Pharmacare (Plan NP).

Special Authority requests can now be submitted online. It's simple and quick!

Learn more or log in

Return to Special Authority drug list

Generic name

Strength

Form

linagliptin

5 mg

tablet

linagliptin-metformin

2.5 mg/500 mg
2.5 mg/850 mg
2.5 mg/1000 mg

tablet

Special Authority criteria	Approval period
As part of a combination treatment for type 2 diabetes mellitus: After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea or dual therapy of metformin and an insulin	Indefinite

Special Authority criteria

Approval period

As part of a combination treatment for type 2 diabetes mellitus:

After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea or dual therapy of metformin and an insulin

Indefinite

Practitioner exemptions

None

Special notes

Patients who meet the limited coverage criteria for linagliptin automatically receive coverage for saxagliptin

Special Authority request form(s)

Log in to eForms
HLTH 5481 – Third-Line Anti-Diabetic Drugs (PDF, 672KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics